Mobile Proxy Healthcare Data
Healthcare research runs on public registries and national formularies — trial registers, regulator databases, reimbursement lists. Almost all of it is open, most of it is national, and none of it should ever involve patient data.
- The valuable sources are open registries — trial registers and regulator databases are published deliberately and are pleasant to work with.
- Availability and price are national — the same medicine has a different status, label and reimbursement in each country.
- Patient data is never in scope — health data is a special category under European law and simply is not a collection target.
- Slow cadence is correct — registries update on a scale of days, and public-health sources deserve light-touch traffic.
Reach each country’s own reimbursement and label data.
Source, version and date beside every record.
Healthcare Data Research
Healthcare is unusual in this cluster because the most valuable sources are the ones that want to be read. Clinical trial registers publish protocols, sites, status and results. Regulator databases publish approvals, labels, safety communications and full product information. National bodies publish reimbursement decisions and formulary status. All of it is deliberately public, structured, and maintained by organisations whose purpose is dissemination.
What makes it a distributed collection problem is that a medicine is not one thing internationally. Approval status, the approved indication, the label text, the reimbursement decision and the price all differ country by country, and each country publishes its own version through its own body. Tracking a product across markets therefore means collecting from each market, not querying one source repeatedly.
| Source category | What it holds | Why it is national |
|---|---|---|
| Trial registers | Protocols, recruiting status, sites, posted results | Registration obligations and registries differ by region |
| Regulator databases | Approvals, indications, label text, safety notices | Each authority approves and labels independently |
| Formularies and reimbursement | Whether a product is funded, at what level, with what restrictions | Funding decisions are made and published per health system |
| Pricing and availability | List and reimbursed prices, supply notices, shortages | Prices are negotiated nationally and published nationally |
Medical Information Gathering
Because regulatory documents are revised in place and superseded quietly, provenance matters more here than almost anywhere else. A label is amended, an indication is widened, a safety communication supersedes an earlier one — and the page keeps the same address throughout. A record without a version and a fetch date cannot be compared with anything later, including its own earlier self.
source … # authority or registry document_id … version … # or revision date as published fetched_at 2026-08-24T09:14:02Z market DE # the health system this applies to supersedes … # if the source states it
The other habit worth building is restraint about cadence. These are public-health services funded to serve clinicians and patients, and their content changes on a scale of days to months. A research crawl should be invisible in their traffic — daily at the very most, weekly for most purposes, and never parallelised for the sake of finishing sooner.
Health Industry Trends
The genuinely interesting analysis in this vertical is comparative and longitudinal, which is exactly what multi-market collection makes possible. How long does a product take to move from approval in one health system to reimbursement in another. Which indications are widening and where. Where are trials recruiting this year that were not last year. Which markets are reporting supply problems for the same molecule.
None of those questions can be answered from a snapshot, and none can be answered from one country. They need the same collection running consistently across several markets for long enough that the differences become a series rather than an anecdote — which puts continuity, not coverage, at the centre of the design.
- Track status transitions, not states — The date a trial changed to recruiting is a signal; the fact that it is recruiting today is not.
- Normalise the product, not the record — The same molecule carries different brand names per market. Resolve to an ingredient identifier or the comparison silently fails.
- Keep the original language — Store the source text as published and translate downstream. Translation at collection time destroys evidence.
Privacy Considerations in Healthcare Data
This one is short because it is not complicated. Health data about identifiable people is a special category under European data protection law, carrying a high bar for any processing at all, and equivalent protections exist across most jurisdictions. It is not a target, it is not a grey area to be navigated carefully, and a research programme has no reason to go near it.
Everything of value in this vertical exists at product, trial or population level. Approvals, labels, funding decisions, recruitment status, supply notices and published aggregate outcomes are all published deliberately and identify nobody. A collection design that stays at that level never has to ask the question, which is a considerably better position than answering it well.
Patient forums, review sites and social posts describing individual health experiences are personal data of the most sensitive kind, whatever their access settings. Treat them as out of scope rather than as a source with caveats.
For the general collection discipline see web scraping best practices, and for designing a multi-market sample, market research.
Reach Each Country’s Health Sources
Live PXM2 locations — pick the markets whose formularies, labels and approvals you track:
France
India
Singapore
Frequently Asked Questions
Which healthcare sources are actually worth collecting?
The open registries, overwhelmingly. Clinical trial registers publish protocol, status, sites and results. Regulator databases publish approvals, labels, safety communications and product information. National bodies publish reimbursement decisions and formulary status. All of it is deliberately public, structured, and intended to be read — which makes it both the most useful and the least contentious material in the vertical.
Why does any of this need a local exit?
Because a medicine is not one thing internationally. Approval status, the approved indication, the label text, the reimbursement decision and the price all differ by country, and each country publishes its own version through its own body. Several national services also render poorly or restrict access to foreign addresses. Tracking a product across markets therefore means collecting from each market rather than from one vantage point.
Is patient data ever in scope?
No. Health data about identifiable people is a special category under European data protection law with a correspondingly high bar, and equivalent protections exist in most jurisdictions. It is not a target, it is not a grey area, and a research programme has no reason to touch it. Everything worth having in this vertical is published at product, trial or population level.
How often should these sources be checked?
Daily at most, and weekly is usually right. Trial statuses, approvals and formulary decisions change on a scale of days to months, so a fast cadence buys nothing. There is also a courtesy argument that carries real weight here: these are public-health services funded to serve clinicians and patients, and a research crawl should be invisible in their traffic.
What has to be recorded with each observation?
The source, the document version or revision date, the date you collected it, and the market. Regulatory documents are revised in place and superseded quietly, so a record without a version and a fetch date cannot be compared with anything later — including its own earlier self.
Related Mobile Proxy Guides
Healthcare shares its national-source pattern with the other regulated verticals in this cluster.
Business use cases
Core mobile proxy guides
Track Each Health System Separately
Dedicated 4G/5G modems with unlimited bandwidth and unlimited rotations — carrier IPs in the markets whose formularies and approvals you follow.
Get a Mobile Proxy